ART26.12

ART26.12

Identifiers
IUPAC name (2R,4R)-3-(2,3-dihydro-1H-inden-2-yloxycarbonyl)-2,4-bis(2-methoxyphenyl)cyclobutane-1-carboxylic acid
CAS Number	2766800-24-0
PubChem CID	163249803
Chemical and physical data
Formula	C29H28O6
Molar mass	472.537 g·mol−1
3D model (JSmol)	Interactive image
SMILES COC1=CC=CC=C1[C@@H]2C([C@H](C2C(=O)OC3CC4=CC=CC=C4C3)C5=CC=CC=C5OC)C(=O)O
InChI InChI=1S/C29H28O6/c1-33-22-13-7-5-11-20(22)24-26(28(30)31)25(21-12-6-8-14-23(21)34-2)27(24)29(32)35-19-15-17-9-3-4-10-18(17)16-19/h3-14,19,24-27H,15-16H2,1-2H3,(H,30,31)/t24-,25-,26?,27?/m1/s1 Key:HFKXLDACQCGGEI-BINWOUKTSA-N

ART26.12 is an experimental drug that acts as a selective inhibitor of the enzyme FABP5, which usually breaks down endocannabinoids such as anandamide. ART26.12 thereby boosts endocannabinoid levels and has analgesic effects, showing efficacy against atypical pain syndromes such as hyperalgesia and allodynia. It is being researched as a potential treatment for neuropathy which can occur as a side effect of some kinds of chemotherapy, as well as showing activity against psoriasis. ^{[1] [2] [3] [4]}

References

1. Warren G, Osborn M, Tsantoulas C, David-Pereira A, Cohn D, Duffy P, et al. (July 2024). "Discovery and Preclinical Evaluation of a Novel Inhibitor of FABP5, ART26.12, Effective in Oxaliplatin-Induced Peripheral Neuropathy". The Journal of Pain. 25 (7): 104470. doi:10.1016/j.jpain.2024.01.335. PMID   38232863.
2. Warren WG, Osborn M, Duffy P, Yates A, O'Sullivan SE (October 2024). "Potential safety implications of fatty acid-binding protein inhibition". Toxicology and Applied Pharmacology. 491: 117079. Bibcode:2024ToxAP.49117079W. doi: 10.1016/j.taap.2024.117079 . PMID   39218163.
3. Warren WG, Osborn M, David-Pereira A, Tsantoulas C, Xue W, Yates A, et al. (February 2025). "ART26.12, a novel fatty acid-binding protein 5 inhibitor, shows efficacy in multiple preclinical neuropathy models". European Journal of Pain. 29 (2). London, England: e4718. doi:10.1002/ejp.4718. PMC   11671339 . PMID   39188040.
4. Warren WG, Osborn M, Yates A, O'Sullivan SE (April 2025). "ART26.12, a fatty acid-binding protein 5 inhibitor, shows efficacy in preclinical psoriasis models". The Journal of Investigative Dermatology. doi:10.1016/j.jid.2025.03.026. PMID   40210114.